Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-09-05
2006-09-05
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S053000, C514S054000, C514S056000, C514S061000, C514S062000, C536S018700, C536S020000, C536S021000, C536S022100, C536S029100, C536S029130, C536S123100
Reexamination Certificate
active
07101859
ABSTRACT:
The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of disease states, including obstructive respiratory disease, including asthma; colitis and Crohn's disease; central nervous system insult, including blood brain barrier compromise, ischemic stroke, and multiple sclerosis; contact dermatitis; psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; sepsis; acute respiratory distress syndrome; tissue transplant rejection syndromes; autoimmune disease; viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of phosphatidylethanolamine bound to carboxymethylcellulose, heparin, hyaluronic acid, polyethylene glycol, and Polygeline (haemaccel). Disclosed herein are also new compounds comprised of phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.
REFERENCES:
patent: 5064817 (1991-11-01), Yedgar et al.
patent: 5464942 (1995-11-01), Sakurai et al.
patent: 5470578 (1995-11-01), Aoki et al.
patent: 6022866 (2000-02-01), Falk et al.
patent: 6043231 (2000-03-01), Pruzanski et al.
patent: 6071532 (2000-06-01), Chaikof et al.
patent: 6162787 (2000-12-01), Sorgente et al.
patent: 6171614 (2001-01-01), Chaikof et al.
patent: 0581282 (1994-02-01), None
patent: 09030979 (1997-02-01), None
patent: WO 9628544 (1996-09-01), None
patent: WO 9701330 (1997-01-01), None
patent: WO 98016198 (1998-04-01), None
Group V Phospholipase A2-mediated Oletic Acid Mobilization in Lipopolysaccharide-stimulated P388D1Macrophages; Balsinde Jesus, Balboa Maria A., Yedgar Saul, and Dennis Edward A., The Journal of Biological Chemistry, vol. 275, Feb. 18 pp. 4783-4786.
Inhibition of LPS-induced chemokine production in human lund endothelial cells by lipid conjugates achored to the membrane Beck, G. Ch, Yard B.A. Schulte J., Oberacker. R, Van Ackern K, Van Der Woude F.J, Krimsky M, Kaszkin M and Yedgar Y.; British Journal of Pharmacology (2002) 135, 1665-1674.
Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A2; Chem, W.M, Soria J, Coria C, Krimsky M and Yedgar S.; FEBS 26215 letters 522 (2002) 113-118.
Interaction of hyacluronic acid-linked phophatidylethonolmine (HyPE) with LDL and its effect on the susceptibility of LDL lips to oxidation; Schnitzer Edit, Dagan Arie, Krimsky Miron, Lichtenberg Dov, Pinchuk Ilya, Shinar Hadassa, Yedgar Saul; CPL 104 (2000) 149-160.
Inhibition of phopholipase A2 as a therapeutic target; Yedgar Saul, Lichtenberg Dov, Schnitzer Edit, BBA Biochimica et Biophyscia Acta 1488 (2000) 182-187.
Albini, A, Iwamoto, Y, Kleinman, HK, Martin, GR, Aaronson, SA, Kozlowski, JM and McEwan, RN (1987) “A rapid in vitro assay for quantitating the invasive potential of tumor cells”Cancer Res47(12):3239-45.
Cabanas, C and Hogg, N (1993) “Ligand intercellular adhesion molecule 1 has a necessary role in activation of integrin lymphocyte function-associated molecule 1”Proc Natl Acad Sci U S A90(12):5838-42.
Dan, P, Dagan, A, Krimsky, M, Pruzanski, W, Vadas, P and Yedgar, S (1998) “Inhibition of type 1 and type II phospholipase A2 by phosphatidyl-ethanolamine linked to polymeric carriers”Biochemistry37(17):6199-204.
Greaves, MW and Camp, RD (1988) “Prostaglandins. leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin”Arch Dermatol Res280:S33-41.
Krimsky, M, Dagan, A, Aptekar, L, Ligumsky, M and Yedgar, S (2000) “Assessment of intestinal permeability in rats by permeation of inulin-fluorescein”J Basic Clin Physiol Pharmacol11(2):143-53.
Krimsky, M, Yedgar, S, Aptekar, L, Schwob, O, Goshen, G, Gruzman, A, Sasson, S and Ligumsky, M (2003) “Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor”Am J Physiol Gastrointest Liver Physiol285(3):G586-92.
Margolis-Nunno, H, Ben-Hur, E, Gottlieb, P, Robinson, R, Oetjen, J and Horowitz, B (1996) “Inactivation by phthalocyanine pholosensitization of multiple forms of human immunodeficiency virus in red cell concentrates”Transfusion36(8):743-50.
Murthy, SN, Cooper, HS, Shim, H, Shah, RS, Ibrahim, SA and Sedergran, DJ (1993) “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin”Diq Dis Sci38(9):1722-34.
Okayasu, I, Hatakeyama, S, Yamada, M, Ohkusa, T, Inagaki, Y and Nakaya, R (1990) “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice”Gastroenterology98(3):694-702.
Schmiel, DH and Miller, VL (1999) “Bacterial phospholipases and pathogenesis”Microbes Infect1(13):1103-12.
Schnitzer, E, Pinchuk, I, Fainaru, M, Lichtenberg, D and Yedgar, S (1998) “LDL-associated phospholipase A does not protect LDL against lipid peroxidation in vitro”Free Radic Biol Med24(7-8):1294-303.
Schnitzer, E, Yedgar, S, Danino, D, Talmon, Y and Lichtenberg D (1999) “The interaction of hyaluronic-phosphatidylethanolamine with low density lipoprotein (LDL) and its effect on copper induced LDL oxidation”Biophysical Journal76(1): Part 2.
Beck Grietje
Krimsky Miron
van der Woude Fokko Johannes
Yard Benito Antonio
Yedgar Saul
Cohen Mark S.
O'Sullivan Peter
Pearl Cohen Zedek Latzer LLP
Yissum Research Development Company of The Hebrew University of
LandOfFree
Use of lipid conjugates in the treatment of diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of lipid conjugates in the treatment of diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of lipid conjugates in the treatment of diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549969